Laura Mauri

Q: What Schools Are Affiliated With Laura Mauri

Laura Mauri is affiliated with the following schools: University of Porto, McMaster University, University of Washington, Massachusetts General Hospital, University of Nebraska Medical Center

Laura Mauri's AcademicInfluence.com Rankings

Laura Mauri

Philosophy

#8246

World Rank

#11588

Historical Rank

Logic

#5280

World Rank

#6667

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Laura Mauri's Degrees

Doctorate Medicine Harvard University

Why Is Laura Mauri Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Laura Mauri's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions (2007) (5088)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. (2011) (2418)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. (2011) (2262)
A controlled trial of renal denervation for resistant hypertension. (2014) (1851)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) (1802)
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. (2014) (1564)
Stent thrombosis in randomized clinical trials of drug-eluting stents. (2007) (1484)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (1234)
Percutaneous repair or surgery for mitral regurgitation. (2011) (1199)
Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). (2014) (1122)
Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models (2007) (1092)
Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. (2012) (997)
Closure or medical therapy for cryptogenic stroke with patent foramen ovale. (2012) (951)
[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018) (913)
2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infa (2016) (866)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. (2011) (720)
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. (2016) (693)
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention (2013) (682)
Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. (2015) (609)
Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. (2012) (536)
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. (2015) (477)
4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. (2013) (417)
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial (2018) (413)
Complete Revascularization with Multivessel PCI for Myocardial Infarction. (2019) (399)
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (396)
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. (2006) (366)
Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. (2014) (364)
Coronary Artery Spatial Distribution of Acute Myocardial Infarction Occlusions (2004) (349)
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. (2015) (342)
Percutaneous Mitral Annuloplasty for Functional Mitral Regurgitation: Results of the CARILLON Mitral Annuloplasty Device European Union Study (2009) (341)
A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. (2009) (300)
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. (2018) (285)
Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. (2007) (250)
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials (2018) (248)
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. (2010) (242)
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. (2015) (240)
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis (2013) (231)
Late Loss in Lumen Diameter and Binary Restenosis for Drug-Eluting Stent Comparison (2005) (199)
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial (2017) (186)
Challenges in the Design and Interpretation of Noninferiority Trials (2017) (185)
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. (2014) (182)
The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. (2010) (179)
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. (2018) (172)
The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. (2007) (169)
Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry. (2016) (169)
Drug-eluting or bare-metal stents for acute myocardial infarction. (2008) (166)
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent (2010) (162)
Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis (2015) (161)
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial (2012) (158)
Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts (2008) (157)
Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis (2015) (153)
Relationship Between the Magnitude of Reduction in Mitral Regurgitation Severity and Left Ventricular and Left Atrial Reverse Remodeling After MitraClip Therapy (2013) (152)
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary (2012) (149)
Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. (2011) (149)
Saphenous Vein Graft Stenting and Major Adverse Cardiac Events: A Predictive Model Derived From a Pooled Analysis of 3958 Patients (2008) (148)
Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. (2002) (140)
Robustness of Late Lumen Loss in Discriminating Drug-Eluting Stents Across Variable Observational and Randomized Trials (2005) (140)
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. (2018) (139)
Saphenous vein graft intervention. (2011) (132)
Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus: Results From the Massachusetts Data Analysis Center Registry (2008) (129)
Rationale and design of the DeFACTO (Determination of Fractional Flow Reserve by Anatomic Computed Tomographic AngiOgraphy) study. (2011) (127)
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. (2010) (119)
Carotid artery stenting with emboli protection surveillance study: Thirty‐day results of the CASES‐PMS study (2007) (118)
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary (2011) (117)
Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial (2015) (117)
Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents (2005) (117)
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. (2015) (104)
Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. (2017) (96)
Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. (2007) (96)
Effects of stent length and lesion length on coronary restenosis. (2004) (93)
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial (2021) (93)
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. (2015) (93)
The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. (2006) (89)
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. (2016) (89)
Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). (2003) (88)
Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry (2010) (87)
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. (2013) (84)
Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials (2007) (83)
EVEREST II randomized clinical trial: predictors of mitral valve replacement in de novo surgery or after the MitraClip procedure. (2012) (82)
Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. (2005) (82)
A Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure with Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2, Randomized, Sham-Controlled Trial (2017) (78)
Drug-eluting stenting for unprotected left main coronary artery disease: are we ready to replace bypass surgery? (2006) (76)
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. (2016) (75)
Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. (2008) (74)
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. (2013) (72)
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. (2005) (68)
Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. (2009) (68)
Lack of Association Between Migraine Headache and Patent Foramen Ovale: Results of a Case-Control Study (2010) (67)
Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention (2011) (66)
Devices for distal protection during percutaneous coronary revascularization. (2006) (66)
Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial: A Randomized, Multicenter Comparison of the NEVO Sirolimus-Eluting Coronary Stent With the TAXUS Liberté Paclitaxel-Eluting Stent in De Novo Native Coronary Artery Lesions (2010) (65)
Adherence to Dual Antiplatelet Therapy After Coronary Stenting: A Systematic Review (2014) (65)
Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberté Paclitaxel-Eluting Coronary Stent Placement (2015) (64)
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. (2012) (63)
3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. (2008) (63)
2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: A Proposal to Optimize Care for Patients With Valvular Heart Disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascula (2019) (61)
A Prediction Model to Identify Patients at High Risk for 30-Day Readmission After Percutaneous Coronary Intervention (2013) (60)
Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. (2013) (60)
Nonemergency PCI at hospitals with or without on-site cardiac surgery. (2013) (56)
Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. (2015) (55)
Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. (2014) (55)
Sources of Hospital Variation in Short-Term Readmission Rates After Percutaneous Coronary Intervention (2012) (55)
Rationale and design of the HeartFlowNXT (HeartFlow analysis of coronary blood flow using CT angiography: NeXt sTeps) study. (2013) (55)
Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Elu (2009) (55)
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I) (2016) (55)
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. (2016) (54)
Repeat Revascularization After Contemporary Percutaneous Coronary Intervention: An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year (2012) (54)
Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial. (2012) (53)
A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. (2018) (53)
Frequency and Clinical Consequences Associated With Sidebranch Occlusion During Stent Implantation Using Zotarolimus-Eluting and Paclitaxel-Eluting Coronary Stents (2009) (51)
Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. (2010) (51)
Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. (2009) (51)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. (2009) (50)
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. (2014) (50)
Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. (2010) (47)
Causes of Short-Term Readmission After Percutaneous Coronary Intervention (2014) (47)
Risk Prediction for Adverse Events After Carotid Artery Stenting in Higher Surgical Risk Patients (2012) (47)
Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. (2011) (45)
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study (2016) (45)
Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. (2015) (45)
Risk‐Treatment Paradox in the Selection of Transradial Access for Percutaneous Coronary Intervention (2013) (44)
Women in interventional cardiology: Update in percutaneous coronary intervention practice patterns and outcomes of female operators from the National Cardiovascular Data Registry® (2016) (44)
Causes of late mortality with dual antiplatelet therapy after coronary stents. (2015) (43)
Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials (2014) (42)
Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. (2009) (41)
Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. (2019) (39)
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. (2015) (39)
Renal denervation therapy for hypertension: pathways for moving development forward. (2015) (39)
Population trends in rates of coronary revascularization. (2015) (38)
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. (2015) (38)
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. (2017) (37)
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (2016) (36)
Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). (2015) (35)
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. (2015) (35)
A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. (2008) (35)
The conundrum of late and very late stent thrombosis following drug-eluting stent implantation (2007) (35)
Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of "falsification hypotheses" in observational studies of comparative effectiveness. (2013) (34)
Clinical Preventability of 30‐Day Readmission After Percutaneous Coronary Intervention (2014) (34)
Right ventricular perforation and pulmonary embolism with polymethylmethacrylate cement after percutaneous kyphoplasty. (2013) (33)
Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials). (2010) (33)
Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry’s CathPCI Registry (2016) (33)
Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients (2018) (33)
Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: A meta‐analysis and critical examination of current methodologies (2014) (32)
Why we still need randomized trials to compare effectiveness. (2012) (31)
European registry of carotid artery stenting: Results from a prospective registry of eight high volume EUROPEAN institutions (2012) (30)
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program (2013) (28)
Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. (2016) (28)
Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis (2016) (28)
Long-term clinical outcomes following drug-eluting or bare-metal stent placement in patients with severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. (2011) (27)
5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. (2017) (26)
Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: Results From a Propensity Score–Matched Analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry (2011) (26)
Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. (2012) (26)
Enhancing the Prediction of 30-Day Readmission After Percutaneous Coronary Intervention Using Data Extracted by Querying of the Electronic Health Record (2015) (26)
Interventional Therapy Versus Medical Therapy for Secundum Atrial Septal Defect: A Systematic Review (Part 2) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease (2018) (25)
Distinct Mechanical Stimuli Differentially Regulate the PI3K/Akt Survival Pathway in Endothelial Cells (2000) (24)
Update on antithrombotic therapy after percutaneous coronary revascularisation (2017) (23)
Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy). (2010) (23)
Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: a model for protection from acute myocardial infarction. (2010) (22)
Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. (2017) (21)
Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? (2014) (21)
Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) (21)
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis (2018) (21)
Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial: Comparing Hospitals and Patients in the Dual Antiplatelet Therapy Study Versus the National Cardiovascular Data Registry (2015) (20)
Location of acute coronary artery thromboses in patients with and without chronic kidney disease. (2009) (20)
Rationale and design of the EVOLVE Short DAPT Study to assess 3‐month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention (2018) (20)
Usefulness of Intracoronary Brachytherapy for Patients With Resistant Drug-Eluting Stent Restenosis. (2017) (19)
Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. (2019) (19)
One-year outcomes of percutaneous coronary intervention with the 38-mm Resolute zotarolimus-eluting stent. (2013) (19)
Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial). (2011) (19)
Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II). (2019) (19)
Performance of the resolute zotarolimus‐eluting stent in small vessels (2014) (18)
Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right (2015) (18)
Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study (2016) (18)
Paclitaxel exposure: Long‐term safety and effectiveness of a drug‐coated balloon for claudication in pooled randomized trials (2020) (18)
Sex‐specific outcomes following revascularization with zotarolimus‐eluting stents: Comparison of angiographic and late‐term clinical results (2010) (17)
Percutaneous Mitral Annuloplasty for Functional Mitral Regurgitation (2009) (16)
Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. (2016) (16)
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial (2022) (14)
Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions. (2013) (14)
Statistical analysis of noncommensurate multiple outcomes. (2011) (14)
Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. (2019) (14)
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy) (2017) (14)
Antiplatelet Therapy After Coronary Stenting (2013) (13)
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention (2020) (13)
Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non–ST-Segment–Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States (2017) (13)
Instrumental Variable Analysis to Compare Effectiveness of Stents in the Extremely Elderly (2014) (13)
Studies of Drug-Eluting Stents: To Each His Own? (2008) (12)
Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus‐eluting coronary stent system using a Bayesian approach (2017) (12)
Long‐term efficacy and safety of zotarolimus‐eluting stent in patients with diabetes mellitus: Pooled 5‐year results from the ENDEAVOR III and IV trials (2013) (12)
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. (2009) (12)
Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among US Cardiologists (2014) (12)
Impact of body mass index on long‐term clinical outcomes after second‐generation drug eluting stent implantation: Insights from the international global RESOLUTE program (2015) (12)
Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial. (2017) (11)
Optimal timing of noncardiac surgery after stents. (2012) (11)
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. (2019) (11)
2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: A Proposal to Optimize Care for Patients With Valvular Heart Disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascula (2019) (11)
2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: A proposal to optimize care for patients with valvular heart disease: A joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascula (2019) (11)
Real-World Safety and Effectiveness Outcomes of a Zotarolimus-Eluting Stent: Final 3-Year Report of the RESOLUTE International Study (2013) (10)
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study (2021) (10)
Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped? (2006) (10)
Nonculprit lesions--innocent or guilty by association. (2013) (10)
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study (2017) (10)
2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: A proposal to optimize care for patients with valvular heart disease (2019) (9)
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. (2021) (9)
Drug-Eluting Stents in the Elderly (2010) (9)
Controversies in the use of drug-eluting stents for acute myocardial infarction: a critical appraisal of the data. (2010) (8)
TCT-786 Cost Effectiveness of the MitraClip® Compared with Mitral Valve Surgery: 12-month Results from the EVEREST II Randomized Controlled Trial (2012) (8)
Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. (2020) (8)
Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study: Findings From the EXTEND-DAPT Study. (2021) (8)
5-YEAR FINAL RESULTS OF THE SISR (SIROLIMUS-ELUTING STENTS VERSUS VASCULAR BRACHYTHERAPY FOR IN-STENT RESTENOSIS) TRIAL (2011) (8)
Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right (2015) (8)
THE RELATIONSHIP BETWEEN SHORT AND LONG–TERM ANTIPLATELET THERAPY USE AND STENT THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION WITH THE RESOLUTE ZOTAROLIMUS–ELUTING STENT (2013) (8)
TCT-788 The EVEREST II Randomized Controlled Trial (RCT): Three Year Outcomes (2012) (7)
Addendum to: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary (2019) (7)
Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women: Results From the DAPT Study (2018) (7)
TCT-19 Fractional Flow Reserved Derived From Computed Tomographic Angiography (FFRCT) for Intermediate Severity Coronary Lesions: Results from the DeFACTO Trial (Determination of Fractional Flow Reserve by Anatomic Computed TOmographic Angiography) (2012) (7)
CRT-832 EVEREST II REALISM - A Continued Access Study To Evaluate The Safety And Effectiveness Of The MitraClip Device: Demographics And Procedural Outcomes (2015) (7)
Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program. (2016) (7)
Duration of dual antiplatelet therapy after drug-eluting stents. (2015) (7)
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial (2020) (6)
FINAL RESULTS OF THE EVEREST II RANDOMIZED CONTROLLED TRIAL OF PERCUTAENOUS AND SURGICAL REDUCTION OF MITRAL REGURGITATION (2014) (6)
CKD and coronary collateral supply in individuals undergoing coronary angiography after myocardial infarction. (2012) (6)
Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction A (2016) (6)
Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease. (2016) (6)
Frequency of Stent Thrombosis Risk at 5 Years in Women Versus Men With Zotarolimus-Eluting Compared With Sirolimus-Eluting Stent. (2016) (5)
The DAPT Score in Sweden: Successful Validation, Flawed Interpretation. (2019) (5)
Angiographic characteristics of coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease (2013) (5)
THE RESOLUTE ZOTAROLIMUS-ELUTING STENT IN PATIENTS WIH DIABETES MELLITUS: TWO YEAR OUTCOMES (2012) (5)
Coronary artery disease Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction : a collaborative meta-analysis of randomized trials (2016) (5)
Late loss in a disappearing frame of reference: is it still applicable to fully absorbable scaffolds? (2009) (5)
Choosing Methods to Minimize Confounding in Observational Studies: Do the Ends Justify the Means? (2011) (5)
Long‐term (5‐year) clinical evaluation of the Resolute zotarolimus‐eluting coronary stent: The RESOLUTE US clinical trial (2020) (5)
MYOCARDIAL INFARCTION AFTER LATE DISCONTINUATION OF THIENOPYRIDINE THERAPY IN THE RANDOMIZED DAPT STUDY (2016) (4)
FIVE YEAR CLINICAL RESULTS FROM ENDEAVOR III: A RANDOMIZED COMPARISON OF THE ZOTAROLIMUS-ELUTING VERSUS SIROLIMUS-ELUTING STENTS IN DE NOVO NATIVE CORONARY LESIONS (2010) (4)
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. (2015) (4)
Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). (2019) (4)
Valvular heart disease in the pregnant patient (2001) (3)
Angiography and Interventions Association Task Force on Practice Guidelines and the Society for Cardiovascular Summary : A Report of the American College of Cardiology Foundation/American Heart 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive (2012) (3)
TCT-405 SYMPLICITY HTN-3: Outcomes in the African-American and non-African American Populations (2014) (3)
Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site. (2011) (3)
Renal denervation for the treatment of hypertension: Making a new start, getting it right (2015) (3)
An evidence-based approach to the use of drug-eluting stents in clinical practice. (2004) (3)
Final results from the multi-center trial of the angiosculpt scoring balloon catheter for the treatment of complex coronary artery lesions (2006) (3)
STEEP DECLINES IN POPULATION RATES OF CORONARY REVASCULARIZATION (2014) (3)
Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. (2010) (3)
The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale. (2019) (3)
Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy. (2015) (3)
Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). (2014) (2)
Abstract 4499: Outcomes Following Primary Percutaneous Coronary Intervention: A Comparison Between Hospitals With and Without Cardiac Surgery On-Site (2009) (2)
P3180The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCI trial (2018) (2)
Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications. (2018) (2)
the Society for Cardiovascular Angiography and Interventions Foundation/American Heart Association Task Force on Practice Guidelines and Executive Summary : A Report of the American College of Cardiology 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: (2011) (2)
Thrombosis, bleeding and DAPT non-adherence in the EDUCATE registry (2013) (2)
Clinical review of the Resolute® zotarolimus-eluting stent for the treatment of coronary artery disease (2012) (2)
Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug‐coated balloon in subjects with stenotic lesions of the femoropopliteal artery — the TRANSCEND study (2019) (2)
PREDICTORS OF RECURRENT NEUROLOGIC EVENTS IN PATIENTS WITH PATENT FORAMEN OVALE: INSIGHTS FROM THE CLOSURE I TRIAL (2013) (2)
RADIANCE-HTN SOLO: A MULTICENTER, RANDOMIZED, SHAM-CONTROLLED STUDY OF RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION IN THE ABSENCE OF ANTIHYPERTENSIVE MEDICATIONS (2018) (2)
Predictors of clinical and angiographic restenosis in the Sirolimus-Eluting Bx VELOCITY stent trial (2003) (2)
Abstract 2536: Impact Of Moderate Renal Insufficiency on Restenosis and Adverse Clinical Events After Sirolimus-eluting and Bare Metal Stent Implantation: Results from the Sirius Trials (2008) (2)
Abstract 14773: Risk-Treatment Paradox in the Selection of Transradial Access for Percutaneous Coronary Intervention: An Opportunity for Quality Improvement (2012) (1)
EFFECTIVENESS OF TRANSCATHETER REDUCTION OF SIGNIFICANT MITRAL REGURGITATION IN HIGH SURGICAL RISK PATIENTS WITH MITRACLIP: FINAL 5 YEAR RESULTS OF THE EVEREST II HIGH RISK REGISTRY (2014) (1)
Acute Coronary Syndrome in a 52-Year-Old Woman With Scleroderma (2016) (1)
Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the dilatation vs. ablation revascularization trial targeting restenosis (DART)☆ (2003) (1)
Late stent thrombosis: can it be prevented? (2014) (1)
BALANCING RISKS OF BLEEDING AND STENT THROMBOSIS: A DECISION ANALYTIC MODEL TO COMPARE DURATION OF DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTS (2014) (1)
Does the beneficial effect of distal protection in saphenous vein graft interventions vary with lesion length? A SAFER (Saphenous Vein Graft Angioplasty Free of Emboli Randomized) substudy (2002) (1)
RELATION OF STROKE AND BLEEDING RISK PROFILES TO EFFICACY AND SAFETY OF DABIGATRAN IN ATRIAL FIBRILLATION AFTER PCI: AN ANCILLARY ANALYSIS FROM THE RE-DUAL PCI TRIAL (2018) (1)
IMPACT OF CORONARY ANATOMICAL COMPLEXITY ON THE EFFECT OF EXTENDED DURATION DUAL ANTIPLATELET THERAPY: AN ANALYSIS FROM THE DUAL ANTIPLATELET THERAPY STUDY (2017) (1)
TCT-10 Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization (2013) (1)
Prospective Feasibility Trial Investigating the se of the Impella 2 . 5 System in Patients ndergoing High-Risk Percutaneous Coronary ntervention ( The PROTECT I Trial ) (2009) (1)
USEFULNESS OF ATHEROSCLEROTIC PLAQUE DIFFUSENESS AND VOLUME BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY FOR PREDICTING CORONARY LESION-SPECIFIC ISCHEMIA BY FRACTIONAL FLOW RESERVE (2016) (1)
PCI at hospitals with or without on-site cardiac surgery. (2013) (1)
The ''RADIANCE-HTN'' clinical study: a two-cohort study design to evaluate the effectiveness of the paradise renal denervation system in patients with hypertension (2016) (1)
Reply: Duration of the Double Antiplatelet Therapy in Patients With Coronary and Peripheral Arterial Disease: The Key Might Be in the Type of Drug. (2017) (1)
Ambulatory blood pressure results of symplicity HTN-3 trial (2014) (1)
zotarolimus-eluting stent for the treatment of coronary artery disease (2012) (1)
DURATION OF DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENT TREATMENT BY GEOGRAPHIC REGION (2012) (1)
Predictive Models Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and (2007) (1)
TEMPORAL TRENDS IN ADMISSION STATUS AND PREDICTED MORTALITY AMONG PATIENTS UNDERGOING NON-ACUTE PERCUTANEOUS CORONARY INTERVENTION: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY (2015) (1)
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits Part 1 - Health Benefits (2006) (1)
LATE-TERM SAFETY AND EFFICACY OUTCOMES FOLLOWING TREATMENT WITH ZOTAROLIMUS-ELUTING STENTS: 5-YEAR RESULTS OF THE POOLED ENDEAVOR TRIALS PROGRAM (2010) (1)
CRT-70 The Resolute Zotarolimus-eluting Stent Is Equally Safe And Effective In Women And Men With Coronary Artery Disease: Two-year Outcomes From The Pooled Resolute Clinical Program (2013) (1)
Renal Denervation: Where to Now? (2015) (1)
Impact On Outcome Of Different Types Of Carotid Stents: Results From The European Registry Of Carotid Artery Stenting (2013) (1)
Reply: Analysis of Dual Antiplatelet Therapy. (2015) (1)
SELECTIVE DRUG-ELUTING STENT USE IN ELDERLY PATIENTS: IMPACT ON PERCUTANEOUS CORONARY INTERVENTION MORTALITY AND BLEEDING RISK (2012) (1)
Letter by Kereiakes et al regarding article, "Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern". (2007) (1)
TCT-639 Two Year Outcomes Following Implantation of the Resolute Zotarolimus-eluting Stent in Vessels ≤2.5 mm Diameter (2012) (1)
FOUR-YEAR OUTCOMES FOLLOWING RESOLUTE ZOTAROLIMUS-ELUTING STENT IMPLANTATION: RESOLUTE US STUDY (2014) (0)
RF36 ISOLATED COARCTATION OF THE AORTA: 10 YEARS EXPERIENCE (2018) (0)
Abstract 15708: Does Targeted Low Dose Heparin Negate the Efficacy and Safety of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention? Insights from a Propensity Score Matched Analysis of the EVENT Registry (2010) (0)
Pulse on Spontaneous Coronary Artery Dissections (2017) (0)
Abstract 14804: Acute and 3-year Bleeding Risks: Comparing Drug-Eluting to Bare-Metal Stents in Old and Very Old Adults in a Community Population (2010) (0)
Abstract P108: Assessing Utility of Drug-Eluting Stents in Coronary Patients Aged 85 Years and Older (2011) (0)
TCT-742 Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From PROTECT (2012) (0)
Abstract 19004: The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis (2016) (0)
EFFECTIVENESS OF BIVALIRUDIN VERSUS UNFRACTIONATED HEPARIN DURING PERCUTANEOUS CORONARY INTERVENTION AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN THE UNITED STATES (2016) (0)
BIOFLOW V: COMPARISON OF ULTRATHIN SIROLIMUS-ELUTING BIORESORBABLE POLYMER STENTS WITH THIN EVEROLIMUS-ELUTING DURABLE POLYMER STENTS - TARGET VESSEL MYOCARDIAL INFARCTION ANALYSIS (2018) (0)
Abstract 9351: Are “All-Comer” Clinical Trials Representative of Contemporary Clinical Practice: A Linked Analysis of the Dual Antiplatelet Therapy (DAPT) Study and the National Cardiovascular Data Registry® (2013) (0)
LONG-TERM OUTCOMES OF PATIENTS TREATED WITH ZOTAROLIMUS-ELUTING STENTS IN DIFFERENT INDICATIONS: ST ELEVATION MYOCARDIAL INFARCTION VERSUS ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION VERSUS STABLE ANGINA: A POOLED ANALYSIS FROM THE RESOLUTE PROGRAM (2012) (0)
TCT-841 Baseline characteristics and 3-month outcomes of the EVOLVE Short DAPT Trial: A prospective investigation of abbreviated antiplatelet therapy in high bleeding risk patients treated with a thin-strut bioabsorbable polymer-coated, everolimus-eluting coronary stent (2018) (0)
ASSOCIATION BETWEEN PREDICTED RISK OF RECURRENT ISCHEMIC EVENTS AND ACHIEVEMENT OF SECONDARY PREVENTION GOALS AFTER PCI (2017) (0)
Response to Letters Regarding Article, “Lack of Association Between Migraine Headache and Patent Foramen Ovale: Results of a Case-Control Study” (2010) (0)
Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. (2015) (0)
Feldman, T. et al. (2018) Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP- HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): (2017) (0)
TCT-646 Primary Results Following Percutaneous Coronary Intervention with the 38 mm Resolute Zotarolimus-eluting Stent (2012) (0)
Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents : Primary Endpoint Results from the Dual Antiplatelet Therapy Study (2014) (0)
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease (2011) (0)
Dual antiplatelet therapy duration and mortality – Authors' reply (2015) (0)
TCT-85 Ventricular and Atrial Remodeling after the Percutaneous MitraClip: 4 year Follow-up Data from the EVEREST II Randomized Controlled Trial (2013) (0)
Antiplatelet Therapy and Coronary Stents (2009) (0)
LONG-TERM (FIVE-YEAR) CLINICAL EVALUATION OF THE RESOLUTE CORONARY ZOTAROLIMUS-ELUTING STENT: THE RESOLUTE US CLINICAL TRIAL (2015) (0)
DAPT Study: Benefits Seen with Prolonged DAPT after DES Treatment (2014) (0)
THE RELATIONSHIP BETWEEN THE MAGNITUDE OF REDUCTION IN MITRAL REGURGITATION SEVERITY AND LEFT VENTRICULAR AND LEFT ATRIAL VOLUMES POST-TREATMENT WITH THE MITRACLIP DEVICE (2012) (0)
IMPACT OF PERIPROCEDURAL MYOCARDIAL BIOMARKER ELEVATION ON MORTALITY FOLLOWING PERCUTANEOUS CORONARY INTERVENTION: A POOLED PATIENT-LEVEL (N=13452) ANALYSIS OF CONTEMPORARY STENT TRIALS (2018) (0)
Left Atrial Appendage Occlusion Devices Versus Pharmacological Agents for Stroke Prevention in Atrial Fibrillation (2017) (0)
DUAL ANTIPLATELET THERAPY BEYOND ONE YEAR FOLLOWING CORONARY STENTING IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION: A DUAL ANTIPLATELET THERAPY STUDY ANALYSIS (2016) (0)
Abstract 5993: One-Year Clinical Outcomes of Sirolimus-Eluting vs. Paclitaxel-Eluting Stents in Unselected Patients: Results from the Multicenter EVENT Registry (2008) (0)
Abstract 321: A Validated Model to Identify Patients at High Risk for 30-Day Readmission After Percutaneous Coronary Intervention (2012) (0)
on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions the American College of Cardiology Foundation/American Heart Association Task Force 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A Report of (2012) (0)
Erratum: Long-term clinical outcomes with Zotarolimus-eluting versus bare-metal coronary stents (J Am Coll Cardiol Intv (2010) 3 (1240-1249)) (2011) (0)
POOLED ANALYSIS OF LONG–TERM SAFETY DATA FROM THE RESOLUTE CLINICAL TRIAL PROGRAM (2012) (0)
Abstract 4600: Long-Term Clinical Outcomes Following Drug-eluting and Bare Metal Stenting in Patients With Chronic Kidney Disease in Massachusetts (2009) (0)
Response to letters regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement". (2015) (0)
Predicting Outcomes in Individual Patients After Transcatheter Aortic Valve Replacement: Small Steps on the Path to Improved Decision Making. (2016) (0)
Abstract P4: Does the Expected Reduction in Restenosis from Drug-Eluting Stents Predict Actual Use? An Assessment of Treatment-Risk Paradox Using the C-Statistic (2011) (0)
Mortality risk with dual antiplatelet therapy? (2015) (0)
In response to the letter to the editor of Cikirikcioglu et al regarding “The EVEREST II Trial: Design and rationale for a randomized study of the Evalve MitraClip system compared with mitral valve surgery for mitral regurgitation” (2011) (0)
Abstract 14912: Preventability of 30-Day Readmission After PCI (2013) (0)
Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease (2019) (0)
omparison of Zotarolimus-Eluting nd Sirolimus-Eluting Stents in Patients ith Native Coronary Artery Disease Randomized Controlled Trial avid (2006) (0)
Diabetic heart disease and interventional cardiology: how can clinical outcomes be improved? Revascularization guided by hemodynamic parameters (fractional flow reserve). (2013) (0)
Abstract 5451: Coronary Spatial Distribution of Non-ST Elevation Myocardial Infarction is Non-Uniform and Clustered in the Proximal Portion of the Coronary Tree (2009) (0)
Abstract 71: Causes of 30-day Readmission Rates after Percutaneous Coronary Intervention - Lessons from Direct Chart Review (2013) (0)
Drug-Eluting Stents Prevent Death, MI, and Revascularization in Patients with Diabetes (2009) (0)
BENEFIT AND RISK OF DUAL ANTIPLATELET THERAPY IN FEMALES: DAPT STUDY RESULTS (2016) (0)
Coronary Atherosclerotic Plaque Burden Predicts Myocardial Infarction (2008) (0)
Abstract 1680: Spatial Distribution of Myocardial Infarction in Patients with Diabetes Mellitus (2007) (0)
Bioresorbable polymer drug-eluting stents – Authors' reply (2018) (0)
EVEREST II HIGH RISK COHORT: BASELINE CHARACTERISTICS AND ONE-YEAR OUTCOMES IN MEN VS WOMEN (2012) (0)
Infective endocarditis. (2001) (0)
DAPT Study: Bleeding Increased but No Difference in Bleeding-Related Mortality (2015) (0)
ASSESSING OUTCOMES IN THE DUAL ANTIPLATELET (DAPT) CLINICAL TRIAL USING MEDICARE CLAIMS: INSIGHTS FROM THE EXTEND-DAPT STUDY (2019) (0)
ASSESSING FRAILTY-ASSOCIATED CHARACTERISTICS AND OUTCOMES IN THE DUAL ANTIPLATELET THERAPY (DAPT) STUDY USING MEDICARE CLAIMS: INSIGHTS FROM THE EXTEND-DAPT STUDY (2020) (0)
Abstract 17162: Early and Late Stent Thrombosis are Associated with Long-Term Cardiac Mortality: Results from Pooled PROTECT Trials (2014) (0)
Baseline characteristics of Patients On and Off OMt Patient characteristic On OMt Off OMt (2016) (0)
Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: how much is acceptable? (2013) (0)
Abstract 345: High Risk Characteristics of Patients Returning Within 30 Days After PCI with Chest Discomfort (2014) (0)
TEMPORAL TRENDS AND OPERATOR VARIATION IN ANTICOAGULANT USE DURING PERCUTANEOUS CORONARY INTERVENTION FOR PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN THE UNITED STATES (2016) (0)
TEMPORAL TRENDS IN CARE AND OUTCOMES OF PATIENTS WITH CARDIOGENIC SHOCK UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A REPORT FROM THE NCDR® (2015) (0)
Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models Statistical (2007) (0)
Abstract 17725: Growth in Non-Emergency PCI at Hospitals Without Surgery-On-Site Since the Completion of the MASS COMM Trial - A Comparison of the MASS COMM RCT and Cohort Study (2013) (0)
Primer on Statistical Interpretation or Methods Statistical Analysis of Noncommensurate Multiple Outcomes (2011) (0)
Abstract 12267: Clinical Significance of Very Late Ischemic and Bleeding Events After Percutaneous Coronary Intervention (2015) (0)
LONG-TERM DUAL ANTIPLATELET THERAPY WITH TICAGRELOR AFTER DRUG-ELUTING STENTS: RESULTS OF A DECISION ANALYTIC MODEL (2015) (0)
Noninferiority Trials. (2018) (0)
urrogates , Substudies , and Real Clinical nd Points in Trials of Drug-Eluting Stents (0)
Outcomes in Drug-Eluting Stents Comparable to Bare Metal Stents: Results of the MASS Stent Trial (2007) (0)
2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: A Proposal to Optimize Care for Patients With Valvular Heart Disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascula (2019) (0)
Drug-Eluting Stents Found to Be Safe and Effective in Patients with MI (2008) (0)
Advances in Clinical Trials (2016) (0)
Predictors of stent thrombosis from 30 days to 3 years after zotarolimus- vs sirolimus-eluting coronary stent implantation: an analysis from PROTECT (2013) (0)
The DAPT Score in Sweden (2018) (0)
Abstract 19526: Fractional Flow Reserved Derived from Computed Tomographic Angiography (FFRCT) to Discriminate Individuals with versus without Ischemia: Results from the DeFACTO Trial (Determination of Fractional Flow Reserve by Anatomic Computed TOmographic Angiography) (2012) (0)
Restenosis, statistics, and reasonable inferences. Authors' replay (2006) (0)
2 YEAR CLINICAL OUTCOMES FROM THE PIVOTAL RESOLUTE US STUDY (2012) (0)
Response by Resor and Mauri to Letter Regarding Article, "Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study". (2017) (0)
Abstract 2161: Impact of Target Lesion Revascularization During the First Year After Bare-Metal or Sirolimus-Eluting Stenting on Five-Year Cardiac Outcomes (2007) (0)
TCT-649 Safety and Efficacy of Overlapping Second Generation Drug-Eluting Stents Based Upon 2-year Clinical outcomes. Results from the Pooled Analysis of Five Trials from the International Global RESOLUTE Program (2012) (0)
THREE–YEAR FOLLOW–UP OF THE RESOLUTE US CLINICAL TRIAL (2013) (0)
Abstract 23231: The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis (2016) (0)
Abstract 15170: Extended Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Among Patients With Peripheral Arterial Disease: A Sub-Analysis of the Dual Antiplatelet Therapy Study (2016) (0)
Abstract 147: Do Billing Data Accurately Describe Causes Of Readmission After PCI? An Analysis Of A Large PCI Readmission Database. (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Laura Mauri?

Laura Mauri is affiliated with the following schools: